Stool DNA Testing and Colon Cancer Prevention: Another Step Forward
Authors: Daniel C. Chung
Journal: Annals of Internal Medicine (2008)

Editorials7 October 2008Stool DNA Testing and Colon Cancer Prevention: Another Step ForwardDaniel C. Chung, MDDaniel C. Chung, MDFrom Massachusetts General Hospital, Boston, MA 02114.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-7-200810070-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Despite the recognition that colon cancer is largely preventable, it remains the second leading cause of cancer-related deaths in the United States. Historically, screening approaches have sought to detect established cancer, but the identification of precancerous adenomatous polyps is clearly the preferable goal. Not all adenomas progress to cancer, but those that are larger than 1 cm or contain villous histology or high-grade dysplasia are most likely to do so. The current multisociety guidelines now emphasize detection of precancerous polyps as the most effective strategy to prevent deaths from colon cancer, and structural examinations, such as colonoscopy, are recommended for ...References1. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J; et al.. American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570-95. [PMID: 18384785] CrossrefMedlineGoogle Scholar2. Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555-60. [PMID: 11529208] CrossrefMedlineGoogle Scholar3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-67. [PMID: 2188735] CrossrefMedlineGoogle Scholar4. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P; et al.. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256:102-5. [PMID: 1566048] CrossrefMedlineGoogle Scholar5. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-14. [PMID: 15616205] CrossrefMedlineGoogle Scholar6. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ; et al.. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441-50. LinkGoogle Scholar7. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536-40. [PMID: 7951326] CrossrefMedlineGoogle Scholar8. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP; et al.. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135:489-98. [PMID: 18602395] CrossrefMedlineGoogle Scholar9. Zou H, Harrington JJ, Loprinzi C, Levin T, Rex D, Ahnen D; et al.. Stool DNA screening of colorectal neoplasia: improved adenoma detection rate by novel digital melt curve assay [Abstract]. Gastroenterology. 2008;134:A109. CrossrefGoogle Scholar10. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S; et al.. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111-7. [PMID: 17161655] CrossrefMedlineGoogle Scholar11. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:96-104. [PMID: 12118964] LinkGoogle Scholar12. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126:1270-9. [PMID: 15131787] CrossrefMedlineGoogle Scholar13. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L; et al.. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97:1124-32. [PMID: 16077070] CrossrefMedlineGoogle Scholar14. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E; et al.. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244-55. [PMID: 17310048] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Massachusetts General Hospital, Boston, MA 02114.Disclosures:Grants received: D.C. Chung (EXACT Sciences, 2001–2003).Corresponding Author: Daniel C. Chung, MD, Gastrointestinal Unit and Cancer Center, GRJ 825, Massachusetts General Hospital, 50 Blossom Street, Boston, MA 02114; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoStool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia David A. Ahlquist , Daniel J. Sargent , Charles L. Loprinzi , Theodore R. Levin , Douglas K. Rex , Dennis J. Ahnen , Kandice Knigge , M. Peter Lance , Lawrence J. Burgart , Stanley R. Hamilton , James E. Allison , Michael J. Lawson , Mary E. Devens , Jonathan J. Harrington , and Shauna L. Hillman Metrics Cited by1 H NMR Spectroscopy of Fecal Extracts Enables Detection of Advanced Colorectal NeoplasiaValidation of methylation-sensitive high-resolution melting (MS-HRM) for the detection of stool DNA methylation in colorectal neoplasmsLowly Expressed Ribosomal Protein S19 in the Feces of Patients with Colorectal CancerFecal Molecular Markers for Colorectal Cancer ScreeningCost-effectiveness of Colorectal Cancer ScreeningRapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresisFem1b antigen in the stool of ApcMin mice as a biomarker of early Wnt signaling activation in intestinal neoplasiaStool DNA Testing to Screen for Colorectal Cancer in the Medicare Population A Cost-Effectiveness AnalysisIris Lansdorp-Vogelaar, PhD, Karen M. Kuntz, ScD, Amy B. Knudsen, PhD, Janneke A. Wilschut, MS, Ann G. Zauber, PhD, and Marjolein van Ballegooijen, MD, PhDCost-effectiveness of colorectal cancer screening – An overviewComprehensive Outpatient Health Assessment 7 October 2008Volume 149, Issue 7Page: 509-510KeywordsAdenomasCancer screeningColonoscopyColorectal cancerDNAGenetic testingHematologic testsMethylationMutationSpecificity ePublished: 7 October 2008 Issue Published: 7 October 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...